Peak6 Investments LP Lowered Its Glaxosmithkline Plc (GSK) Stake; ACADIA Pharmaceuticals Inc. (ACAD) Covered By 9 Bullish Analysts Last Week

February 16, 2018 - By Migdalia James

Among 12 analysts covering ACADIA Pharmaceuticals (NASDAQ:ACAD), 9 have Buy rating, 0 Sell and 3 Hold. Therefore 75% are positive. ACADIA Pharmaceuticals had 33 analyst reports since August 7, 2015 according to SRatingsIntel. Jefferies maintained the stock with “Buy” rating in Monday, September 4 report. Piper Jaffray maintained ACADIA Pharmaceuticals Inc. (NASDAQ:ACAD) on Thursday, October 5 with “Buy” rating. Bank of America upgraded the stock to “Buy” rating in Tuesday, November 8 report. As per Monday, August 10, the company rating was upgraded by Vetr. Piper Jaffray upgraded it to “Neutral” rating and $48.0 target in Thursday, August 27 report. On Thursday, October 5 the stock rating was maintained by H.C. Wainwright with “Buy”. Goldman Sachs initiated the shares of ACAD in report on Friday, November 11 with “Neutral” rating. The rating was maintained by Cowen & Co with “Outperform” on Sunday, August 9. The rating was upgraded by Piper Jaffray on Friday, January 22 to “Overweight”. The rating was reinitiated by Ladenburg Thalmann with “Buy” on Thursday, February 2. See ACADIA Pharmaceuticals Inc. (NASDAQ:ACAD) latest ratings:

13/11/2017 Broker: Cowen & Co Rating: Buy New Target: $50.0 Maintain
08/11/2017 Broker: J.P. Morgan Rating: Buy New Target: $50.0 Maintain
08/11/2017 Broker: H.C. Wainwright Rating: Buy New Target: $60.0 Maintain
07/11/2017 Broker: Cowen & Co Rating: Buy New Target: $46.0 Maintain
10/10/2017 Broker: Jefferies Rating: Buy New Target: $47.0 Maintain
04/10/2017 Broker: Cowen & Co Rating: Buy New Target: $46.0 Maintain
05/10/2017 Broker: J.P. Morgan Rating: Buy New Target: $50.0 Maintain
05/10/2017 Broker: H.C. Wainwright Rating: Buy New Target: $60.0 Maintain
05/10/2017 Broker: Piper Jaffray Rating: Buy New Target: $61.0 Maintain
15/09/2017 Broker: Needham Rating: Buy New Target: $49.0 Maintain




Peak6 Investments Lp decreased Glaxosmithkline Plc (GSK) stake by 95.4% reported in 2017Q3 SEC filing. Peak6 Investments Lp sold 858,817 shares as Glaxosmithkline Plc (GSK)’s stock rose 5.47%. The Peak6 Investments Lp holds 41,383 shares with $1.68 million value, down from 900,200 last quarter. Glaxosmithkline Plc now has $84.21B valuation. The stock increased 1.00% or $0.37 during the last trading session, reaching $37.68. About 3.83 million shares traded. GlaxoSmithKline plc (NYSE:GSK) has risen 4.26% since February 16, 2017 and is uptrending. It has underperformed by 12.44% the S&P500.

ACADIA Pharmaceuticals Inc., a biopharmaceutical company, focuses on the development and commercialization of small molecule drugs that address unmet medical needs in central nervous system disorders. The company has market cap of $3.84 billion. The Company’s lead product candidate, NUPLAZID, has completed the Phase III pivotal trials for the treatment of ParkinsonÂ’s disease psychosis and the Phase II trial for the treatment of schizophrenia, as well as is in Phase II study for the treatment of AlzheimerÂ’s disease psychosis. It currently has negative earnings. The firm has a collaboration with Allergan, Inc. for the development of product candidates related to chronic pain.

The stock decreased 0.45% or $0.14 during the last trading session, reaching $30.92. About 403,107 shares traded. ACADIA Pharmaceuticals Inc. (NASDAQ:ACAD) has declined 15.19% since February 16, 2017 and is downtrending. It has underperformed by 31.89% the S&P500.

Investors sentiment decreased to 1.01 in 2017 Q3. Its down 0.04, from 1.05 in 2017Q2. It dived, as 25 investors sold ACADIA Pharmaceuticals Inc. shares while 58 reduced holdings. 32 funds opened positions while 52 raised stakes. 113.55 million shares or 1.98% less from 115.85 million shares in 2017Q2 were reported. Soros Fund Management Ltd Liability Corporation reported 18,300 shares or 0.02% of all its holdings. D E Shaw & holds 0% or 18,429 shares in its portfolio. Ig Investment reported 0.01% of its portfolio in ACADIA Pharmaceuticals Inc. (NASDAQ:ACAD). Principal Fincl Group Inc holds 0% of its portfolio in ACADIA Pharmaceuticals Inc. (NASDAQ:ACAD) for 13,329 shares. Lpl Ltd Com owns 93,155 shares or 0.01% of their US portfolio. Pub Employees Retirement Of Ohio holds 0.01% or 37,950 shares in its portfolio. Atlantic Trust Gru Ltd Liability holds 15,195 shares or 0% of its portfolio. 363,392 are held by Morgan Stanley. Amalgamated Commercial Bank accumulated 18,273 shares. Metropolitan Life Insurance New York has invested 0% in ACADIA Pharmaceuticals Inc. (NASDAQ:ACAD). Moreover, Platinum Mngmt Ltd has 0.03% invested in ACADIA Pharmaceuticals Inc. (NASDAQ:ACAD) for 32,300 shares. Family Management holds 0.76% or 29,500 shares in its portfolio. Fifth Third Bankshares holds 0% in ACADIA Pharmaceuticals Inc. (NASDAQ:ACAD) or 4,700 shares. Tocqueville Asset Limited Partnership reported 45,260 shares. Acuta Capital Prtn Limited Liability invested 1.15% of its portfolio in ACADIA Pharmaceuticals Inc. (NASDAQ:ACAD).

Since August 30, 2017, it had 0 insider purchases, and 5 sales for $6.63 million activity. Another trade for 74,321 shares valued at $2.24M was made by Baity Glenn on Tuesday, January 2. Another trade for 25,000 shares valued at $751,543 was sold by Brege Laura.

Among 18 analysts covering GlaxoSmithKline (NYSE:GSK), 8 have Buy rating, 1 Sell and 9 Hold. Therefore 44% are positive. GlaxoSmithKline had 28 analyst reports since September 8, 2015 according to SRatingsIntel. The stock of GlaxoSmithKline plc (NYSE:GSK) has “Buy” rating given on Friday, May 26 by Berenberg. The rating was maintained by J P Morgan Chase Co with “Neutral” on Friday, June 16. The company was maintained on Wednesday, April 26 by JP Morgan. Argus Research maintained GlaxoSmithKline plc (NYSE:GSK) rating on Monday, December 7. Argus Research has “Buy” rating and $48 target. Cowen & Co maintained the stock with “Hold” rating in Wednesday, February 14 report. The rating was upgraded by Bank of America on Tuesday, September 8 to “Neutral”. The firm earned “Buy” rating on Thursday, July 14 by Jefferies. The firm earned “Neutral” rating on Tuesday, September 15 by BNP Paribas. The firm has “Underperform” rating by BNP Paribas given on Wednesday, September 14. The company was upgraded on Wednesday, December 9 by Bank of America.

Peak6 Investments Lp increased Golar Lng Ltd Bermuda (NASDAQ:GLNG) stake by 99,962 shares to 107,462 valued at $2.43M in 2017Q3. It also upped On Semiconductor Corp (ONNN) stake by 18,059 shares and now owns 41,059 shares. Steris Plc (Put) was raised too.

Receive News & Ratings Via Email - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings with our FREE daily email newsletter.